TrialStudy of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Trial details
- Registry ID
- NCT07125872
- Phase
- Phase 2
Drug research
CD19 t-haNK- IV Administration
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872 | IBRX | Phase 2 | Recruiting | 2027-05-25Estimated |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366 | IBRX | Phase 2 | Not yet recruiting | 2027-12Estimated |
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Trial details
- Registry ID
- NCT07477366
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |